2020: 7th National Microbiota Conference
The 7th National Microbiota Conference was held November 16, 2020 and was a fully digital event, supported by Helse Sør-øst and Oslo University Hospital. The event drew close to 160 participants, and covered topics a wide array of topics including microbiome-led mucosial barrier dysfunction, inflammasome activation in Covid-19 patients and gut leakage in heart failure patients
Johannes Hov and Marius Trøseid: Welcome
Hedda Hoel: Elevated Narkers of Gut Leakage and Inflammasome Activation in COVID-19 Patients with Cardiac Involvement
Ayodeji Awoyemi: Effect of Probiotics and Antibiotics on Markers of Gut Leakage in Heart Failure with Reduced Ejection Fraction – Results from the Randomized Controlled GUTHEART Trial
Phil Pope: Designer Fibre for Beneficial Microbes: A Path to Microbiome Modulation
Brian Chung: Altered Immune Recognition of Gut Bacteria by Immunoglobulins in Early Systemic Sclerosis
Rajesh Shigdel: Association of Oral Microbiome with Asthma
Johannes Hov and Marius Trøseid: Discussion and Closing Remarks
Save the date
The 8th National Microbiota Conference will be held November 11, 2021 at Radisson Blu Scandinavia. We hope to see you there!
2019: 6th National Microbiota Conference
The 6th National Microbiota Conference was held November 19, 2019 at the Radisson Blu Scandinavia in Oslo, supported by UiO:Oslo Life Science and Norwegian PSC Research Center and the University of Oslo and Oslo University Hospital. The event drew close to 100 participants this year, and covered topics a wide array of topics including HIV and chronic obstructive pulmonary disease to dietary interventions and fecal microbiota transplantation.
Key Note Speakers and Presentations
The main topic of the conference this year was FMT (Fecal Microbiota Transplantation) and the discussion of the key findings of FMT research, as well as transparency, accessibility, accountability and effectiveness of FMT as a clinical treatment.
Keynote speaker Dr. Christian Lodberg Hvas (University of Aarhus) brought the audience up to date on clinical experience and state of the art FMT treatment in Aarhus, Denmark. Aarhus University Hospital carries out around 200 treatments per year, targeting C. difficile infection, ulcerative colitis, irritable bowel syndrome and multi-drug resistance. The group applies several treatment strategies including endoscopic administration and frozen capsules, but is also working to establish encapsulated lyophilized material as an improvement desired by the patients. Hvas also raised the question on how to organize FMT, pointing out the necessity of a better structure from the donor screening process to final transplantation in order to offer better treatment for the patients.
Peter Holger Johnsen (University Hospital of North Norway, Harstad) presented the establishment of the first donor stool bank in Norway and the thorough screening process of donors that has been applied in the establishment of the biobank. Furthermore, opportunities for collaboration were presented, as the stool bank is also thought to be a source of materials for research projects in the field. Projects already receiving material from the bio-bank are e.g. the multi-centre COLONIZE study, as well as local projects at their hospital, targeting chronic fatigue syndrome, obesity as well as IBS, where a national multicenter study has now been funded.
Michael Bretthauer and Kjetil Garborg (Oslo University Hospital) presented pilot data on microbiota transplantation targeting primary C. difficile infection. The results suggested supply of intestinal microbiota could be as effective as administering standard antibiotics and as such represent a more “physiological” form of treatment. The data has been the basis of the recently started COLONIZE study, which is a randomized multi-center trial targeting primary C. difficile infection with FMT compared with vancomycin. Furthermore, the study hopes to show that FMT treatment in primary C. difficile infection can help reduce the use of antibiotics and costs associated with prolonged hospitalization due to C. difficile infection.
Anna Hoffman-Vold presented the use of bacteriotherapy in systemic sclerosis; an auto-immune multi organ disease with high mortality and no existing modifying treatment, except stem cell therapy which is only available for a small number of patients. Her group has recently performed a pilot study, which included 10 patients as a proof-of-concept of feasibility. They have now received funding for a full trial (the ReSScue Trial), which will utilize Anaerobically Cultivated Human Intestinal Microbiota (ACHIM) and not donor stool. The use of a complex cultivated mixture imposes some legislative challenges, in particular regarding the possible role of the Norwegian Medicines Agency.
Open Abstract Session and the Tore Midtvedt Award
This year, only a selected number of abstracts were presented in oral format. In total 10 abstracts were presented, covering a variety of topics (see program), promoted interesting questions and lively discussions.
The Tore Midtvedt Award has been awarded since 2015 to encourage the submission of scientific contributions, and to honor the pioneer of Norwegian microbiota research Professor Tore Midtvedt. All submitted abstracts are evaluated by an independent jury, who this year selected Beate Vestad for her abstract “Interplay of Gut Microbiota and Immunodeficiency on Excess Metabolic Risk in HIV Infection”.
Save the date
The 7th National Microbiota Conference will be held November 16, 2020 at Radisson Blu Scandinavia. We hope to see you there!
2018: 5th National Microbiota Conference
The 5th National Microbiota Conference is proud to present Harry Sokol and Randi Jacobsen Bertelsen as keynote speakers this year. The focus of the conference will be the Microbiome and Host Immunity, Oral Microbiome and Precision Medicine.
Key Note Speakers
Harry Sokol, Hôpital Saint-Antoine INRA, Paris / Gut Microbiota and Host Immunity – from Mouse Models to Clinical Practice
Randi Jacobsen Bertelsen, University of Bergen / Oral Microbiome in Human Health and Disease
2017: 4th National Microbiota Conference
We are happy to once again invite you to the National Microbiota Conference in Oslo city center. This year’s focus will be the Gut Microbiome; from Biomarker to Clinical Tool. Keynote speaker Cisca Wijmenga from the University of Groningen, Netherlands, will present a Population-Based Approach to Human Metagenomics.
Key Note Speakers
Cisca Wijmenga, University of Groningen / Population-Based Approach to Human Metagenomics
2016: 3rd National Microbiota Conference
We are very happy to welcome you to the third national meeting on microbiota in health and disease, this time in Oslo City Centre. In addition to invited speakers and a particular focus on the gut microbiome in inflammatory diseases, open abstract sessions will once again provide an arena for gut microbiota-related research in Norway.
Key Note Speakers
Karsten Kristiansen, University of Copenhagen / Host Genome and Gut Microbiome in Health and Disease
2015: 2nd National Microbiota Conference
Following the very successful first conference in 2014, we welcome you to the second national meeting on microbiota in health and disease. This year, there will be a particular focus on the gut-brain axis and on the relevance of diet. We well also have open abstract sessions, providing a new forum for presentation of microbiota-related research in Norway.
Key Note Speakers
Rochellys Diaz Heijtz, Karolinska Institutet / Gut Microbiota in Neuroscience
Tone Tønjum, Oslo University Hospital / News on the Gut-Brain Axis: Vesicles, Microbes and DNA Repair
2014: First National Microbiota Conference
The study of the gut microbiota in human health and disease is a rapidly evolving field, which is anticipated to influence clinical practice within a short period of time. We are proud to invite to this first national conference on gut microbiota, providing a meeting place with a scientific and clinical focus.
Key Note Speakers
Tore Midtvedt, Karolinska Institutet / Gut Microbiota in Health and Disease: the History is Long and the Future Bright?
Fredrik Bäckhed, Sahlgrenska Academy / Integrating the Gut Microbiota with Host Physiology